ATE199377T1 - Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung - Google Patents

Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung

Info

Publication number
ATE199377T1
ATE199377T1 AT91403243T AT91403243T ATE199377T1 AT E199377 T1 ATE199377 T1 AT E199377T1 AT 91403243 T AT91403243 T AT 91403243T AT 91403243 T AT91403243 T AT 91403243T AT E199377 T1 ATE199377 T1 AT E199377T1
Authority
AT
Austria
Prior art keywords
protein
production
expression vector
host cells
recombinant dna
Prior art date
Application number
AT91403243T
Other languages
English (en)
Inventor
Daniel Caput
Pascual Ferrara
Brigitte Miloux
Adrian Minty
Natalio Vita
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE199377T1 publication Critical patent/ATE199377T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Peptides Or Proteins (AREA)
AT91403243T 1990-11-29 1991-11-29 Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung ATE199377T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9014961A FR2669930A1 (fr) 1990-11-29 1990-11-29 Proteine presentant une activite de type cytokine, adn recombinant, vecteur d'expression et hotes permettant son obtention.

Publications (1)

Publication Number Publication Date
ATE199377T1 true ATE199377T1 (de) 2001-03-15

Family

ID=9402736

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91403243T ATE199377T1 (de) 1990-11-29 1991-11-29 Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung

Country Status (7)

Country Link
US (1) US6001649A (de)
EP (1) EP0488900B1 (de)
JP (1) JPH05503945A (de)
AT (1) ATE199377T1 (de)
DE (1) DE69132545D1 (de)
FR (1) FR2669930A1 (de)
WO (1) WO1992009629A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100389A (en) * 1995-04-21 2000-08-08 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic protein
ES2165390T3 (es) * 1994-05-16 2002-03-16 Human Genome Sciences Inc Proteina quimiotactica.
US6075124A (en) * 1994-05-16 2000-06-13 Human Genome Sciences, Inc. Human chemotactin protein
WO1995031467A1 (en) * 1994-05-16 1995-11-23 Human Genome Sciences, Inc. Monocyte chemotactic protein-4
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6139832A (en) * 1995-02-08 2000-10-31 Human Genome Sciences, Inc. Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides
US7005509B1 (en) 1995-02-17 2006-02-28 Incyte Corporation Chemokine PANEC-1 polynucleotides and compositions and methods related thereto
US6713605B1 (en) * 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US7265201B1 (en) * 1995-06-23 2007-09-04 Millennium Pharmaceuticals, Inc. Human chemotactic cytokine
US6410268B1 (en) 1996-03-18 2002-06-25 Human Genome Sciences, Inc. Polynucleotides encoding chemokine alpha-3
US5910431A (en) * 1996-03-19 1999-06-08 Human Genome Sciences, Inc. Polynucleotides encoding chemokine α-2
CA2260738A1 (en) * 1996-07-15 1998-01-22 Incyte Pharmaceuticals, Inc. Human monocyte chemotactic proprotein
US6274342B1 (en) 1996-09-18 2001-08-14 Center For Blood Research, Inc. Nucleic acid molecules encoding monocyte chemotactic protein 5 (MCP-5) molecules and uses therefor
US6028169A (en) * 1997-03-31 2000-02-22 Human Genome Sciences, Inc. Chemokine β-6 antagonists
US6562347B1 (en) * 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
WO2002022687A2 (en) * 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
WO2002022686A2 (en) * 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
ATE518884T1 (de) * 2002-05-01 2011-08-15 Human Genome Sciences Inc Spezifisch an chemokin beta-4 bindende antikörper
SG191716A1 (en) 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
FR3031100A1 (fr) 2014-12-31 2016-07-01 Equipement De Chantiers Et Locations Dispositif de chantier perfectionne pour le recyclage d’une eau de lavage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5155297A (en) * 1974-10-28 1976-05-14 Toppan Moore Kk Mihirakya bunryoinakirokubutsuno sakuseihoho
JPS6274652A (ja) * 1985-09-30 1987-04-06 Tokyo Kikai Seisakusho:Kk 発送仕分処理システム
IL92938A (en) * 1989-01-01 1998-08-16 Us Commerce A polypeptide that has a mutagenic activity on monocytes and AND that encodes it
IL92937A0 (en) * 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it

Also Published As

Publication number Publication date
JPH05503945A (ja) 1993-06-24
WO1992009629A1 (fr) 1992-06-11
FR2669930B1 (de) 1995-04-14
EP0488900A1 (de) 1992-06-03
DE69132545D1 (de) 2001-04-05
US6001649A (en) 1999-12-14
FR2669930A1 (fr) 1992-06-05
EP0488900B1 (de) 2001-02-28

Similar Documents

Publication Publication Date Title
DE69132545D1 (de) Protein mit Cytokinaktivität, Rekombinant-DNS, Expressionsvektor und Wirtszellen zu seiner Herstellung
BR9301944A (pt) Derivado de proteina c,molecula de dna recombinante,celula hospedeira e formulacao farmaceutica
DE60040274D1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
CY1107099T1 (el) Παραλλαγες αντισωματων και θραυσματα αυτων
ITTO950367A0 (it) Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti.
EP0657534A4 (de) Antiallergisches agen.
AU1094892A (en) Improved activation of recombinant proteins
DE3484377D1 (de) Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien.
DE69840150D1 (de) Verfahren, basierend auf affinitätskreuzbindung, der interaktion von biologisch aktiven peptiden an antikörper
HUP0002985A2 (hu) Glicirrizinsavat és legalább egy antivirális hatású proteint tartalmazó vírusellenes gyógyszerkészítmény
DE69131426D1 (de) Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone
ATE250129T1 (de) Modifizierte peptidsynthetasen, und deren verwendung in der nicht-ribosomalen herstellung von peptiden
ES2124247T3 (es) Conjugado de calcitonina y de polietilenglicol.
DE69033756D1 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
FI850814A7 (fi) Proteiineja, farmaseuttisia seoksia, geenejä, vektoreita, isäntäorgan ismeja ja menetelmiä niiden tuottamiseksi.
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
DE60026666D1 (de) Induktion von antigen-spezifischen T-Zellen durch Interferon
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
ATE193324T1 (de) Rekombinante herstellung von laktoperoxidase
DE59106997D1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
ATE62268T1 (de) Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien.
MX9708877A (es) P62, sus variantes, las secuencias de acidos nucleicos que los codifican, y su utilizacion en terapia genica anti-cancerosa.
KR950023648A (ko) 생물학적 활성을 나타내는 폴리펩티드